Mindera Health™ announces first patient enrolled in the MATCH Study; a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics
Mind.Px brings personalized medicine to psoriasis patients by improving pre-treatment biologic drug class choice with >90% positive predictive value SAN DIEGO – October 21, 2021 – Mindera Health, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, announced the enrollment of the first patient in the MATCH





